Trials / Unknown
UnknownNCT01492556
Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer
A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe in the treatment of recurrent or metastatic breast cancer in Chinese female patients.
Detailed description
Current recommended dosage of Etoposide in treating breast cancer is 50 mg/m2 orally once a day for 21 days, repeated every 28 days. With retrospective data review, this study intends to adjust Etoposide dose to 60 mg/m2 daily for 10 days, repeated every 21 days as a cycle, to investigate the effectiveness and safety of Etoposide monotherapy in the treatment of recurrent or metastatic breast cancer in Chinese female patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etoposide | Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2014-06-01
- Completion
- 2015-06-01
- First posted
- 2011-12-15
- Last updated
- 2013-03-15
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01492556. Inclusion in this directory is not an endorsement.